AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

CLINUVEL PHARMACEUTICALS LTD

8.130

-0.340-4.01%

Volume:143.21K

Turnover:1.18M

Market Cap:408.13M

PE:12.17

High:8.570

Open:8.470

Low:8.060

Close:8.470

52wk High:13.480

52wk Low:8.060

Shares:50.20M

Float Shares:41.32M

Volume Ratio:2.40

T/O Rate:0.35%

Dividend:0.05

Dividend Rate:0.62%

EPS(TTM):0.668

EPS(LYR):0.718

ROE:13.21%

ROA:8.94%

PB:1.50

PE(LYR):11.32

Loading ...

Overview Company News Filings

Exploring Appen And 2 Promising Tech Stocks With High Growth Potential

Simply Wall St.

Clinuvel Pharmaceuticals; Parmantier & Cie. sets AUD 24 price target, reiterates Buy

ASX 300 healthcare stock outperforming today on 'strategic' leadership news

Clinuvel Pharmaceuticals Retains Philippe Wolgen as CEO

MT Newswires Live

Clinuvel Pharmaceuticals Ltd-Chair Letter to Shareholders

THOMSON REUTERS

Clinuvel Pharmaceuticals - We Expect That Nasdaq Listing for a Level Ii Adr May Be Possible in the First Half of This Year

THOMSON REUTERS

Clinuvel Pharmaceuticals Ltd - Philippe Wolgen to Continue as CEO

THOMSON REUTERS

Morgans says these small-cap ASX shares could rise 30% to 80%

A Look At Clinuvel Pharmaceuticals (ASX:CUV) Valuation After Softer Half Year Earnings Results

Simply Wall St.

Clinuvel Pharmaceuticals announces investor webinar release for the six months ended 31 December 2025

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/CUV.AU/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CUV.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CUV.AU\",,,,,undefined,":{"symbol":"CUV.AU","market":"AU","secType":"STK","nameCN":"CLINUVEL PHARMACEUTICALS LTD","latestPrice":8.13,"timestamp":1788139530761,"preClose":8.47,"halted":0,"volume":143205,"delay":0,"changeRate":-0.04014167650531285,"nameEN":"CLINUVEL PHARMACEUTICALS LTD","floatShares":41318955,"shares":50200740,"eps":0.667999,"marketStatus":"Trading","change":-0.34,"latestTime":"08-31 11:26:21 AEST","open":8.47,"high":8.57,"low":8.06,"amount":1175352,"amplitude":0.060213,"askPrice":8.15,"askSize":250,"bidPrice":8.13,"bidSize":111,"shortable":3,"etf":0,"ttmEps":0.667999,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1788156000000},"marketStatusCode":2,"adr":0,"exchange":"ASX","adjPreClose":8.47,"dividendRate":0.00615,"openAndCloseTimeList":[[1788134400000,1788156000000]],"volumeRatio":2.399424,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"CUV.AU","preClose":8.47,"auctionPrice":8.47,"auctionVolume":12510,"auctionTime":1788134348443,"referenceTime":1787913003093,"auction":1,"marketStatus":"盘前竞价","timestamp":1788134348443}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CUV.AU\",,,,,undefined,":{"symbol":"CUV.AU","floatShares":41318955,"roa":"8.94%","roe":"13.21%","lyrEps":0.717999,"volumeRatio":2.399424,"shares":50200740,"dividePrice":0.05,"high":8.57,"amplitude":0.060213,"preClose":8.47,"low":8.06,"week52Low":8.06,"pbRate":"1.50","psRate":"4.34","week52High":13.48,"institutionHeld":0,"latestPrice":8.13,"committee":-0.385042,"eps":0.667999,"divideRate":0.00615,"volume":143205,"delay":0,"ttmEps":0.667999,"open":8.47,"prevYearClose":12.46,"prevWeekClose":8.47,"prevMonthClose":9.06,"prevQuarterClose":10.28,"fiveDayClose":10.32,"twentyDayClose":9.16,"sixtyDayClose":9.13,"dividendPayoutRate":0.07372445631899688,"dividendFrequency":"A","dividendGrowthYears":6,"dividendGrowthRate":0,"fiveYearAvgDividendRate":0.003390100329748879},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CUV.AU\",params:#limit:5,,,undefined,":[{"date":"2026-09-03","symbol":"CUV.AU","amount":0.05,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2026-09-04","defaultRemindTime":1788393600000,"name":"CLINUVEL PHARMACEUTICALS LTD","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-09-18","payableDate":"2026-09-04","currency":"AUD","dateTimestamp":1788357600000,"payDate":"2026-09-18"},{"date":"2026-08-27","symbol":"CUV.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787788800000,"name":null,"time":"","dateTimestamp":1787752800000,"actualEps":null},{"date":"2026-02-26","symbol":"CUV.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1772060400000,"name":null,"time":"","dateTimestamp":1772024400000,"actualEps":null},{"date":"2025-09-04","symbol":"CUV.AU","amount":0.05,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2025-09-05","defaultRemindTime":1756944000000,"name":"CLINUVEL PHARMACEUTICALS LTD","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-19","payableDate":"2025-09-05","currency":"AUD","dateTimestamp":1756908000000,"payDate":"2025-09-19"},{"date":"2025-08-28","symbol":"CUV.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756339200000,"name":null,"time":"","dateTimestamp":1756303200000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CUV.AU\",market:\"AU\",,,undefined,":[{"executeDate":"2020-09-03","recordDate":"2020-09-04","paymentDate":"2020-09-18","value":0.025,"currency":"AUD"},{"executeDate":"2021-09-02","recordDate":"2021-09-03","paymentDate":"2021-09-17","value":0.025,"currency":"AUD"},{"executeDate":"2022-09-06","recordDate":"2022-09-07","paymentDate":"2022-09-21","value":0.04,"currency":"AUD"},{"executeDate":"2023-09-05","recordDate":"2023-09-06","paymentDate":"2023-09-20","value":0.05,"currency":"AUD"},{"executeDate":"2024-09-05","recordDate":"2024-09-06","paymentDate":"2024-09-20","value":0.05,"currency":"AUD"}],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CUV.AU\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2622895958","title":"Exploring Appen And 2 Promising Tech Stocks With High Growth Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2622895958","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622895958?lang=en_us&edition=fundamental","pubTime":"2026-03-27 03:05","pubTimestamp":1774551958,"startTime":"0","endTime":"0","summary":"Amidst a cautiously optimistic Australian market, with the ASX 200 showing modest gains due to ongoing geopolitical uncertainties, investors are keeping a close eye on sectors poised for growth despite the broader sentiment. In this environment, high-growth tech stocks like Appen and others can be particularly appealing as they offer potential for significant returns by leveraging innovative solutions and adapting swiftly to changing market dynamics.","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/8031000-choice2-main-header/1585186598236","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/8031000-choice2-main-header/1585186598236"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/software/asx-apx/appen-shares/news/exploring-appen-and-2-promising-tech-stocks-with-high-growth","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/software/asx-apx/appen-shares/news/exploring-appen-and-2-promising-tech-stocks-with-high-growth","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["APX.AU","BK4585","BK4543","AGIX","BK7067","BK7016","BK7503","BK7061","CHAT","BK4588","AIPO","AI","BK4528","AIYY","BK4551","BK4587","CUV.AU","FCL.AU","BK7508","BK4023"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622852860","title":"Clinuvel Pharmaceuticals; Parmantier & Cie. sets AUD 24 price target, reiterates Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2622852860","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622852860?lang=en_us&edition=fundamental","pubTime":"2026-03-26 19:46","pubTimestamp":1774525563,"startTime":"0","endTime":"0","summary":"Parmantier & Cie. initiated an update on Clinuvel with a Buy recommendation and a 12-month target price of AUD 24.Analysts Thomas Schiessle and Daniel Grojohann cited revenue growth of 4% and an OPEX increase of 22%.EPS was reported down 26% alongside higher development-related spending.NEURACTHEL Instant  was described as a planned second revenue source with potential of USD 150 million.Philippe Wolgen was expected to continue as CEO, and a Nasdaq Level II ADR uplisting was described as in progress.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clinuvel Pharmaceuticals Limited published the original content used to generate this news brief via EQS News, a service of EQS Group AG , on March 26, 2026, and is solely responsible for the ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDL9k833R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","CUV.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620277043","title":"ASX 300 healthcare stock outperforming today on 'strategic' leadership news","url":"https://stock-news.laohu8.com/highlight/detail?id=2620277043","media":"MotleyFool","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620277043?lang=en_us&edition=fundamental","pubTime":"2026-03-20 08:00","pubTimestamp":1773964847,"startTime":"0","endTime":"0","summary":"Over the past 12 months, shares in the ASX 300 healthcare stock have slumped 20% Addressing that decline, Rosenfeld said, \"Market data tell a clear story: pre-revenue biotechs often outperform as perception and hope dominates investment decisions, while profitable companies executing quietly can be undervalued.\" He added: The board, market analysts, and sophisticated institutions recognise that our share price does not reflect the company's performance. It reflects a perceived ceiling on further growth. Our job, and Philippe's, is to break through that ceiling.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"motleyfoolau_stock","url":"https://www.fool.com.au/2026/03/20/asx-300-healthcare-stock-outperforming-today-on-strategic-leadership-news/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2026/03/20/asx-300-healthcare-stock-outperforming-today-on-strategic-leadership-news/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["CUV.AU","BK7067","XKO.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620277689","title":"Clinuvel Pharmaceuticals Retains Philippe Wolgen as CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2620277689","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620277689?lang=en_us&edition=fundamental","pubTime":"2026-03-20 07:29","pubTimestamp":1773962952,"startTime":"0","endTime":"0","summary":"Clinuvel Pharmaceuticals  confirmed that Philippe Wolgen will remain chief executive, citing his scientific expertise, regulatory experience, and steady leadership as vital for guiding the company through its key growth phase, according to a Friday Australian bourse filing.The company's shares were up 1% in recent Friday trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CUV.AU","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620927483","title":"Clinuvel Pharmaceuticals Ltd-Chair Letter to Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2620927483","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620927483?lang=en_us&edition=fundamental","pubTime":"2026-03-20 05:30","pubTimestamp":1773955855,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nTUE9D6FZ6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","CUV.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620274866","title":"Clinuvel Pharmaceuticals  - We Expect That Nasdaq Listing for a Level Ii Adr May Be Possible in the First Half of This Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2620274866","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620274866?lang=en_us&edition=fundamental","pubTime":"2026-03-20 05:30","pubTimestamp":1773955855,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nTUE9D6FZ6:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","CUV.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620027485","title":"Clinuvel Pharmaceuticals Ltd - Philippe Wolgen to Continue as CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2620027485","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620027485?lang=en_us&edition=fundamental","pubTime":"2026-03-20 05:30","pubTimestamp":1773955855,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nTUE9D6FZ6:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","CUV.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620027294","title":"Morgans says these small-cap ASX shares could rise 30% to 80%","url":"https://stock-news.laohu8.com/highlight/detail?id=2620027294","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620027294?lang=en_us&edition=fundamental","pubTime":"2026-03-18 08:57","pubTimestamp":1773795437,"startTime":"0","endTime":"0","summary":"Having some exposure to the small side of the market can be a good thing for a balanced portfolio, if your risk tolerance allows for it.After all, the potential returns from small-cap ASX shares can be significantly greater than those on offer with large caps.With that in mind, here are two small-cap shares that Morgans thinks could rise strongly from current levels. Let's see what it is recommending:. This biopharmaceuticals company disappointed Morgans during the first half, with softer-than-expected revenue growth and higher-than-expected cost growth.However, the broker remains positive, especially given that this small-cap ASX share trades on lower-than-normal multiples.As a result, the broker has put a speculative buy rating and $13.00 price target on its shares. This implies potential upside of 30% for investors from current levels. It said:. Whilst we downgrade our FY26-17 EBITDA forecasts by 10-20% reflecting revised guidance, given RDY's robust pipeline, potential catalysts , ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"motleyfoolau_stock","url":"https://www.fool.com.au/2026/03/18/morgans-says-these-small-cap-asx-shares-could-rise-30-to-80/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2026/03/18/morgans-says-these-small-cap-asx-shares-could-rise-30-to-80/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7016","BK7067","RDY.AU","CUV.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618647249","title":"A Look At Clinuvel Pharmaceuticals (ASX:CUV) Valuation After Softer Half Year Earnings Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2618647249","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618647249?lang=en_us&edition=fundamental","pubTime":"2026-03-09 08:20","pubTimestamp":1773015634,"startTime":"0","endTime":"0","summary":"Why Clinuvel’s latest half year result has caught investor attention\nClinuvel Pharmaceuticals (ASX:CUV) has drawn fresh interest after reporting half year earnings to 31 December 2025, with revenue of A$40.56 million and net income of A$10.44 million, both below the prior period.\nSee our latest analysis for Clinuvel Pharmaceuticals.\nAt a share price of A$10.16, Clinuvel’s recent half year result lands against a backdrop of weaker momentum, with a 30 day share price return of 8.14% and a 90...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-cuv/clinuvel-pharmaceuticals-shares/news/a-look-at-clinuvel-pharmaceuticals-asxcuv-valuation-after-so","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-cuv/clinuvel-pharmaceuticals-shares/news/a-look-at-clinuvel-pharmaceuticals-asxcuv-valuation-after-so","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CUV.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617599594","title":"Clinuvel Pharmaceuticals announces investor webinar release for the six months ended 31 December 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2617599594","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617599594?lang=en_us&edition=fundamental","pubTime":"2026-03-05 10:48","pubTimestamp":1772678913,"startTime":"0","endTime":"0","summary":"Clinuvel Pharmaceuticals Limited announced the availability of an investor and analyst webinar  discussing its financial results for the six months ended 31 December 2025, hosted at 18:00 AEDT on 26 February 2026, posted at CLINUVEL news website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clinuvel Pharmaceuticals Limited published the original content used to generate this news brief on March 05, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nNDL7ks45p:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","CUV.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":5,"totalSize":90,"code":"91000000","status":"200"}]}}